This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.
Study Type
OBSERVATIONAL
Enrollment
2,000
intravenous liposomal doxorubicin
Ruijin Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGthe incidence of interstitial pneumonia
interstitial pneumonia is defined as positive CT scan with or without positive respiratory symptoms
Time frame: up to one month after completion of study treatment
overall response rate
percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria
Time frame: 21 days after completion of study treatment
adverse events
number of participants with treatment-related adverse events mainly include liposomal related AEs, eg cardiotoxicity and the incidence of hand-foot syndrome
Time frame: up to 30 days after completion of study treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.